Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1987 Jul;25(1):31–40. doi: 10.1007/BF00199298

The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin

Charles F Scott Jr 1,✉, Victor S Goldmacher 1, John M Lambert 1, Ravi V J Chari 1, Susan Bolender 1, Michael N Gauthier 1, Walter A Blättler 1
PMCID: PMC11038303  PMID: 3496157

Abstract

We prepared an immunoconjugate consisting of a monoclonal antibody recognizing the Thy-1 antigen and the ribosome-inactivating protein gelonin linked by a disulfide bond. This immunotoxin preparation was judged to contain less than 5% free antibody or gelonin. It was highly toxic in vitro in an antigen-specific fashion to the Thy-1 expressing RADA leukemia of A/J mice. The IC50 of this preparation on RADA in vitro was 10−12 M, while the IC50 on the Thy-1 negative S1509a fibrosarcoma of A/J mice was 10−7 M. The toxicity of this immunoconjugate was also measured in a direct proliferation assay and it was found that a 4-h exposure and a 24-h exposure of RADA cells to a 1 nM concentration of immunotoxin killed 90% and 99.9% of cells, respectively. Furthermore, efficacy in vitro was not due to the intrinsic susceptibility of RADA cells to tis type of immunotoxin, as one prepared with gelonin and an antibody recognizing the TLa determinant on this leukemia had no efficacy in vitro. Clearance of the anti-Thy-1-gelonin immunoconjugate from the circulation of A/J mice after i.v. injection was rapid, especially during the first 8 h after injection, possibly because of binding to Thy-1 expressing tissue. Delivery of immunoconjugate to ascitic tumor in vivo was substantially better if the immunoconjugate was given by i.p. injection, rather than by the i.v. route. When given either i.v. or i.p. at the time of i.p. tumor inoculation in vivo, the anti-Thy-1-gelonin immunotoxin showed potency in an antigen-specific fashion; while this immunoconjugate prolonged survival and frequently cured RADA-inoculated mice, neither anti-Thy-1 antibody, gelonin, a combination of the two, nor immunotoxin of irrelevant specificity had any significant effect on survival. Anti-Thy-1-gelonin also had no effect on survival of A/J mice inoculated i.p. with S1509a. Furthermore, it was determined that a single i.p. dose of anti-Thy-1-gelonin killed 90% to 99% cells in vivo, and that the immunoconjugate was about as effective in this model as either adriamycin or cytoxan.

Keywords: Monoclonal Antibody, Leukemia, Disulfide, Disulfide Bond, Proliferation Assay

Footnotes

This work was supported by ImmunoGen Inc. and in part by a grant from the National Institutes of Health, CA-14723

References

  • 1.Arnon R, Sela M. In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev. 1982;62:5. doi: 10.1111/j.1600-065x.1982.tb00387.x. [DOI] [PubMed] [Google Scholar]
  • 2.Awdeh ZL, Williamson AR, Askonas BA. One cell, one immunoglobulin. Biochem J. 1970;116:241. doi: 10.1042/bj1160241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Badger CC, Bernstein ID. Therapy of murine leukemia with a monoclonal antibody against a normal differentiation antigen. J Exp Med. 1983;157:828. doi: 10.1084/jem.157.3.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Barbieri L, Stripe F. Ribosome-inactivating proteins from plants; properties and possible uses. Cancer Surveys. 1982;1:489. [Google Scholar]
  • 5.Bernstein ID, Tam MR, Nowinski R. Mouse leukemia: Therapy with monoclonal antibodies against a thymus differentiation antigen. Science. 1980;207:68. doi: 10.1126/science.6965328. [DOI] [PubMed] [Google Scholar]
  • 6.Bjorn MJ, Ring D, Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res. 1985;45:1214. [PubMed] [Google Scholar]
  • 7.Colombatti M, Bron C. Sensitivity of target cells to immunotoxins: possible role of cell-surface antigens. Immunol Lett. 1985;55:331. [PMC free article] [PubMed] [Google Scholar]
  • 8.Colombatti M, Nabholz M, Gros O, Bron C. Selective killing target cells by antibody-Ricin A chain or antibody gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures. J Immunol. 1983;131:3091. [PubMed] [Google Scholar]
  • 9.Cowan NJ, Secher DS, Cotton RGH, Milstein C. The secretion of a sialic acid-free immunoglobulin. FEBS Lett. 1973;30:343. doi: 10.1016/0014-5793(73)80684-2. [DOI] [PubMed] [Google Scholar]
  • 10.Cox DR. Analysis of binary data. London: Chapman and Hall; 1970. [Google Scholar]
  • 11.Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1984. [Google Scholar]
  • 12.Davignon D, Martz E, Reynolds T, Kurzinuciz K, Springer TA. Lymphocyte function-associated antigen, (LFA-1); a surface antigen distinct from Lyt-2,3 that participates in Tlymphocyte mediated killing. Proc Natl Acad Sci USA. 1981;78:4535. doi: 10.1073/pnas.78.7.4535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Deweger RA, Dullens HFJ, Den Otter W. Eradication of murine lymphoma and melanoma cells by chlorambucil antibody complexes. Immunol Rev. 1982;62:29. doi: 10.1111/j.1600-065x.1982.tb00388.x. [DOI] [PubMed] [Google Scholar]
  • 14.Diener E, Diver JE, Sinha A, Xie S, Vergidis R. Specific immunosuppression by immunotoxins containing daunomycin. Science. 1986;231:148. doi: 10.1126/science.3484557. [DOI] [PubMed] [Google Scholar]
  • 15.Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3-alpha, 6 alpha-diphenylglycoluril. Biochem Biophys Res Commun. 1979;80:849. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  • 16.Fulton RJ, Blakey DC, Knowles PP, Uhr JW, Thorpe PE, Vitetta ES. Purification of Ricin A1, A2, and B chains and characterization of their toxicity. J Biol Chem. 1986;261:5314. [PubMed] [Google Scholar]
  • 17.Further EF, Thilly WG, Penman BW, Liber HL, Rand WM. Quantitative assay for mutation in diploid human lymphoblasts using microtiter plates. Anal Biochem. 1981;110:1–8. doi: 10.1016/0003-2697(81)90103-2. [DOI] [PubMed] [Google Scholar]
  • 18.Giovanella BD, Fogh J (1982) Present and future trends with the nude mouse as a recipient of human tumor transplant. In: The nude mouse in experimental and clinical research vol 2. Academic Press
  • 19.Goldmacher VS, Anderson J, Blättler WA, Lambert JM, Senter PD. Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins. J Immunol. 1985;135:3648–3651. [PubMed] [Google Scholar]
  • 20.Goldmacher VS, Lambert JM, Yau-Young A, Anderson J, Tinnel NL, Kornacki M, Ritz J, Blättler W. Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines. J Immunol. 1986;136:320. [PubMed] [Google Scholar]
  • 21.Greene MI, Perry LL, Benacerraf B. Regulation of the immune response to tumor antigen. V. Modulation of suppressor T cell activity in vivo. Am J Pathol. 1979;95:159. [PMC free article] [PubMed] [Google Scholar]
  • 22.Gunter KC, Kroczek RA, Shevach EM, Germain RN. Functional expression of the murine Thy-1.2 gene in transfected human T cells. J Exp Med. 1986;163:285. doi: 10.1084/jem.163.2.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA. 1982;79:4761. doi: 10.1073/pnas.79.15.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Herlyn DM, Steplewki Z, Herlyn MF, Koprowski H. Inhibition of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980;40:714. [PubMed] [Google Scholar]
  • 25.Houston LL, Nowinski LC. Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against the Thy1.1 antigen. Cancer Res. 1981;41:3913. [PubMed] [Google Scholar]
  • 26.Houston LL, Nowinski RC, Bernstein ID. Specific in vivo localization of monoclonal antibodies directed against the Thy1.1 antigen. J Immunol. 1980;125:837. [PubMed] [Google Scholar]
  • 27.Hwang KM, Foon KA, Cheung DH, Pearson JW, Oldham RV. Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma associated antigen. Cancer Res. 1984;44:4578. [PubMed] [Google Scholar]
  • 28.Jansen FK, Blythman HE, Carriere D, Casellas P, Gros O, Gros P, Laurent JG, Paolucci F, Pau B, Poncelet P, Richer G, Vidal H, Voisin G. Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev. 1982;62:185–216. doi: 10.1111/j.1600-065x.1982.tb00394.x. [DOI] [PubMed] [Google Scholar]
  • 29.Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. JASA. 1958;53:457–581. [Google Scholar]
  • 30.Kishida K, Masuho Y, Masahiki S, Hara T, Fuji A. Ricin-A chain conjugated with monoclonal anti-L210 antibody. In vitro and in vivo anti-tumor activity. Cancer Immunol Immunother. 1983;16:93. doi: 10.1007/BF00199238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kroczek RA, Gunter KC, Seligmann B, Shevach EM. Induction of T cell activation by monoclonal anti-Thy-1 antibodies. J Immunol. 1986;136:4379. [PubMed] [Google Scholar]
  • 32.Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature. 1970;227:681. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  • 33.Lambert JM, Senter PD, Yau-Young A, Blättler W, Goldmacher VS. Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed anti-viral proteins. J Biol Chem. 1985;260:12035. [PubMed] [Google Scholar]
  • 34.Letvin NL, Goldmacher VS, Ritz J, Yetz JM, Schlossman SF, Lambert JM. In vivo administration of lymphocyte-specific monoclonal antibodies in non-human primates: in vivo stability of disulfide-linked immunotoxin conjugates. J Clin Invest. 1986;77:977. doi: 10.1172/JCI112399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.MacDonald HR, Bron C, Rousseaux M, Horvotn M, Cerrottini JC. Production and characterization of monoclonal anti-Thy-1 antibodies that stimulate lymphokine production by cytolytic T cell clones. Eur J Immunol. 1985;15:495. doi: 10.1002/eji.1830150514. [DOI] [PubMed] [Google Scholar]
  • 36.Masui H, Kawamoto T, Sato JD, Wolf B, Sato U, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44:1002. [PubMed] [Google Scholar]
  • 37.Meuer SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Hodgdon JC, Reinherz EL. An alternative pathway of T-cell activation: a functional role for the 50KD T11 sheep erythrocyte receptor protein. Cell. 1984;36:897. doi: 10.1016/0092-8674(84)90039-4. [DOI] [PubMed] [Google Scholar]
  • 38.Moller G (ed) (1982) Antibody carriers of drugs and toxins in tumor therapy. Munksgaard International Publishers, Ltd, Immunol Rev 62 [PubMed]
  • 39.Neville DM, Youle RJ. Monoclonal antibody-Ricin or Ricin A chain hybrids: Kinetic analysis of cell killing for tumor therapy. Immunol Rev. 1982;62:75. doi: 10.1111/j.1600-065x.1982.tb00390.x. [DOI] [PubMed] [Google Scholar]
  • 40.Ohkawa V, Hibi N, Tsukada Y. Evaluation of a conjugate of purified antibodies against human AFP-Dextran-daunomycin to human AFP-producing yolk sac tumor lines. Cancer Immunol Immunother. 1986;22:81. doi: 10.1007/BF00199119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Pimm MV, Jones JA, Price MR, Middle JG, Embleton MJ, Baldwin RW. Tumor localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumor growth with conjugates. Cancer Immunol Immunother. 1982;12:125. [Google Scholar]
  • 42.Pirker R, Fitzgerald DJP, Hamilton TC, Ozols RF, Lard W, Frankel AE, Willingham MC, Pastan I. Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest. 1985;78:1761. doi: 10.1172/JCI112082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ramakrishnan S, Houston LL. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors, pokeweed antiviral protein or Ricin A chain. Cancer Res. 1984;44:1398. [PubMed] [Google Scholar]
  • 44.Raso V. Antibody mediated delivery of toxic molecules to antigen-bearing target cells. Immunol Rev. 1982;62:93. doi: 10.1111/j.1600-065x.1982.tb00391.x. [DOI] [PubMed] [Google Scholar]
  • 45.Raso V, Ritz J, Basala M, Schlossman S. Monoclonal antibody Ricin A chain conjugate selectively cytotoxic for cells bearing the common lymphoblastic leukemia antigen. Cancer Res. 1982;42:457. [PubMed] [Google Scholar]
  • 46.Rowland GF, Axton CA. Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother. 1985;19:1. doi: 10.1007/BF00199304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Rowland GF, Simmonds RG, Gore JA, Marsden CH, Smith W. Drug localization and growth inhibition studies of vindesin-monoclonal anti-CEA conjugates in a human tumor xenograft. Cancer Immunol Immunother. 1986;21:183. doi: 10.1007/BF00199359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Schulz G, Staffileno LK, Reisfeld RA, Dennert G. Eradication of established human melanoma tumors in nude mice by antibody directed target cells. J Exp Med. 1985;161:1315. doi: 10.1084/jem.161.6.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Scott CF Jr, Lambert JM, Goldmacher VS, Blättler WA, Sobel R, Schlossman SF, Benacerraf B (1987) The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies. Submitted for publication [DOI] [PubMed]
  • 50.Seto M, Umemoto H, Saito M, Masuho Y, Hala T, Takahashi T. Monoclonal anti-MM46 antibody: Ricin A chain conjugate in vitro and in vivo antitumor activity. Cancer Res. 1982;42:5201. [PubMed] [Google Scholar]
  • 51.Smyth MJ, Pietersz GA, Classon BJ, McKenzie IFC. Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies. J Natl Cancer Inst. 1986;76:503. [PubMed] [Google Scholar]
  • 52.Steplewski Z, Spira G, Blasczyk M, Lubeck MD, Radbruch A, Illges H, Herlyn D, Rajewsky V, Sharff M. Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class switch variants. Proc Natl Acad Sci USA. 1985;32:8653. doi: 10.1073/pnas.82.24.8653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Stripe F, Olsnes S, Phil A. Gelonin, a new inhibitor of protein synthesis nontoxic to intact cells. J Biol Chem. 1980;74:6947. [PubMed] [Google Scholar]
  • 54.Thorpe PE, Ross WCJ. The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev. 1982;62:119. doi: 10.1111/j.1600-065x.1982.tb00392.x. [DOI] [PubMed] [Google Scholar]
  • 55.Thorpe PE, Brown ANF, Ross WCJ, Cumber AJ, Dejle S, Edwards DC, Davies AJ, Stripe F. Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome inactivating protein gelonin. Eur J Biochem. 1981;116:447. doi: 10.1111/j.1432-1033.1981.tb05356.x. [DOI] [PubMed] [Google Scholar]
  • 56.Thorpe PE, Brown ANG, Bremmer JAG, Jr, Foxwell BMJ, Stripe F. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosomal inactivating protein from Saponaria officinalis: Potent anti-tumor effects in vitro and in vivo. J Natl Cancer Inst. 1985;75:151. [PubMed] [Google Scholar]
  • 57.Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature. 1981;294:171. doi: 10.1038/294171a0. [DOI] [PubMed] [Google Scholar]
  • 58.Vallera DA, Youle RJ, Neville DM, Kersey JH. Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft vs. host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. J Exp Med. 1982;155:949. doi: 10.1084/jem.155.3.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Vitetta ES, Krolick KA, Uhr JW. Neoplastic B cells as targets for antibody Ricin A chain immunotoxins. Immunol Rev. 1982;62:159. doi: 10.1111/j.1600-065x.1982.tb00393.x. [DOI] [PubMed] [Google Scholar]
  • 60.Vitetta ES, Krolick KA, Miyama-Inaba M, Cushley W, Uhr JW. Immunotoxins: a new approach to cancer therapy. Science. 1983;122:644. doi: 10.1126/science.6218613. [DOI] [PubMed] [Google Scholar]
  • 61.Well-Hillman G, Ronge W, Jansen FV, Vallera DA. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Cancer Res. 1985;45:1328. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES